Evidence map›Paper›PMID 35328625›Full record

ArticleInternational journal of molecular sciences2022

Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.

Sanghee Lee, Theresa R Mendoza, Danielle N Burner, Michelle T Muldong, Christina C N Wu, Catalina Arreola-Villanueva, Abril Zuniga, Olga Greenburg, William Y Zhu, Jamillah Murtadha and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Muscle and Bone Defects in Metastatic Disease.Current osteoporosis reports · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 2 countries.

Sanghee LeeDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Theresa R MendozaDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Danielle N BurnerDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-0893-1793
Michelle T MuldongDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Christina C N WuMoores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Catalina Arreola-VillanuevaDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Abril ZunigaDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Olga GreenburgDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
William Y ZhuDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Jamillah MurtadhaDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Evodie KoutouanDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Naomi PinedaDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Hao PhamDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Sung-Gu KangDepartment of Urology, Korea University College of Medicine, Seongbuk-Gu, Seoul 02841, Korea.
Hyun Tae KimDepartment of Urology, School of Medicine, Kyungpook National University, Daegu 41944, Korea.
Gabriel PinedaDepartment of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Kathleen M LennonDepartment of Medicine, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-3043-331X
Nicholas A CacalanoDepartment of Radiation Oncology, University of California, Los Angeles, CA 90095, USA.
Catriona H M JamiesonMoores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Christopher J KaneDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
Anna A KulidjianScripps MD Anderson Cancer Center, La Jolla, CA 92093, USA.
Terry GaasterlandScripps Institution of Oceanography, University of California San Diego, La Jolla, CA 92093, USA.
Christina A M JamiesonDepartment of Urology, University of California San Diego, La Jolla, CA 92093, USA.
University of California San Diego · USKorea University · KRKyungpook National University · KRScripps Institution of Oceanography · USScripps MD Anderson Cancer Center · USUniversity of California, Los Angeles · US

Funding

United States Department of Defense W81XWH-19-1-0672
6 · The paper itself

Abstract

Advanced prostate cancer (PCa) patients with bone metastases are treated with androgen pathway directed therapy (APDT). However, this treatment invariably fails and the cancer becomes castration resistant. To elucidate resistance mechanisms and to provide a more predictive pre-clinical research platform reflecting tumor heterogeneity, we established organoids from a patient-derived xenograft (PDX) model of bone metastatic prostate cancer, PCSD1. APDT-resistant PDX-derived organoids (PDOs) emerged when cultured without androgen or with the anti-androgen, enzalutamide. Transcriptomics revealed up-regulation of neurogenic and steroidogenic genes and down-regulation of DNA repair, cell cycle, circadian pathways and the severe acute respiratory syndrome (SARS)-CoV-2 host viral entry factors, ACE2 and TMPRSS2. Time course analysis of the cell cycle in live cells revealed that enzalutamide induced a gradual transition into a reversible dormant state as shown here for the first time at the single cell level in the context of multi-cellular, 3D living organoids using the

Indexed as

AndrogensAngiotensin-Converting Enzyme 2AnimalsBenzamidesBone NeoplasmsCOVID-19Drug Resistance, NeoplasmGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiceNitrilesOrganoidsPhenylthiohydantoinProstatic NeoplasmsACE2 protein, humanAndrogensAngiotensin-Converting Enzyme 2BenzamidesenzalutamideNitrilesPhenylthiohydantoinReceptors, VirusSerine EndopeptidasesTMPRSS2 protein, humanandrogen pathway directed therapyangiotensin-converting enzyme 2basal-luminal-like hybridbone metastatic prostate cancerdormantenzalutamidepatient-derived organoidspatient-derived xenograftprostate cancer San Diego 1SARS-CoV-2transmembrane protease serine 2

Identifiers

PMID35328625
PMCPMC8952299
OpenAlexW4220990143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.